Top Markets
#1 NKN NKN +183.79%
#2 Black Phoenix Black Phoenix +99.30%
#3 Liquid Mercury Liquid Mercury +33.08%
#4 Codatta Codatta +29.91%
#5 SAFEcoin SAFEcoin +27.08%
#6 Saakuru Saakuru +24.27%
#7 StakeStone StakeStone +24.06%
#8 Arcblock Arcblock +18.53%
#9 Yooldo Games Yooldo Games +18.18%
#10 TronBank TronBank +13.72%
Coin of the day
NKN NKN
設定
言語
日本
通貨
USD
テーマ
Daiichi Sankyo Company, Limited Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

DSNKY
株式のランク #649
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports,... Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
株価
$17.87
時価総額
$33.08B
変化（1日）
-4.44%
変化（1年）
-23.83%
国
JP
取引 Daiichi Sankyo Company, Limited (DSNKY)

カテゴリー

Healthcare
Daiichi Sankyo Company, Limited（DSNKY）のP/E比率
2026 時点のP/E比率 TTM 0
Daiichi Sankyo Company, Limited の最新の財務報告および株価によると、現在の P/E (TTM) は 0 です。2026 年末時点での P/E は 0 でした。
Daiichi Sankyo Company, Limited の P/E 比率の履歴（2026 〜 2026）
各年末のP/E比率
年 P/E比率 変化
提供された日付のデータは十分ではありません。
類似企業や競合他社のP/E比率
企業 P/E比率 P/E比率の差 国
Eli Lilly Eli Lilly
Eli Lilly
LLY.US
 42.86 -
US
AstraZeneca PLC AstraZeneca PLC
AstraZeneca PLC
AZN.US
 28.47 -
GB
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 21.88 -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 92.55 -
US
Novartis AG Novartis AG
Novartis AG
NVS.US
 20.85 -
CH
P/E比率の読み方

株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。

P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。

10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。